You are seeing a free-to-access but limited selection of the activity Altmetric has collected about this research output.
Click here to find out more.
Mendeley readers
Attention Score in Context
| Title |
Hepatitis C virus management: potential impact of nanotechnology
|
|---|---|
| Published in |
Virology Journal, May 2017
|
| DOI | 10.1186/s12985-017-0753-1 |
| Pubmed ID | |
| Authors |
Mostafa H. Elberry, Noureldien H. E. Darwish, Shaker A. Mousa |
| Abstract |
Around 170-200 million individuals have hepatitis C virus (HCV), which represents ~ 3% of the world population, including ~ 3-5 million people in the USA. According to the WHO regional office in the Middle East, Egypt has the highest prevalence in the world, with 7% prevalence in adults. There had been no effective vaccine for HCV; a combination of PEG-Interferon and ribavirin for at least 48 weeks was the standard therapy, but it failed in more than 40% of the patients and has a high cost and serious side effects. The recent introduction of direct-acting antivirals (DAA) resulted in major advances toward the cure of HCV. However, relapse and reduced antiviral efficacy in fibrotic, cirrhotic HCV patients in addition to some undesired effects restrain the full potential of these combinations. There is a need for new approaches for the combinations of different DAA and their targeted delivery using novel nanotechnology approaches. In this review, the role of nanoparticles as a carrier for HCV vaccines, anti-HCV combinations, and their targeted delivery are discussed. |
Mendeley readers
The data shown below were compiled from readership statistics for 91 Mendeley readers of this research output. Click here to see the associated Mendeley record.
Geographical breakdown
| Country | Count | As % |
|---|---|---|
| Unknown | 91 | 100% |
Demographic breakdown
| Readers by professional status | Count | As % |
|---|---|---|
| Student > Bachelor | 13 | 14% |
| Student > Master | 11 | 12% |
| Researcher | 10 | 11% |
| Other | 9 | 10% |
| Student > Ph. D. Student | 7 | 8% |
| Other | 18 | 20% |
| Unknown | 23 | 25% |
| Readers by discipline | Count | As % |
|---|---|---|
| Medicine and Dentistry | 22 | 24% |
| Biochemistry, Genetics and Molecular Biology | 15 | 16% |
| Pharmacology, Toxicology and Pharmaceutical Science | 8 | 9% |
| Immunology and Microbiology | 5 | 5% |
| Chemistry | 4 | 4% |
| Other | 11 | 12% |
| Unknown | 26 | 29% |
Attention Score in Context
This research output has an Altmetric Attention Score of 4. This is our high-level measure of the quality and quantity of online attention that it has received. This Attention Score, as well as the ranking and number of research outputs shown below, was calculated when the research output was last mentioned on 31 May 2017.
All research outputs
#7,280,433
of 22,968,808 outputs
Outputs from Virology Journal
#861
of 3,057 outputs
Outputs of similar age
#115,180
of 310,772 outputs
Outputs of similar age from Virology Journal
#13
of 50 outputs
Altmetric has tracked 22,968,808 research outputs across all sources so far. This one has received more attention than most of these and is in the 67th percentile.
So far Altmetric has tracked 3,057 research outputs from this source. They typically receive a lot more attention than average, with a mean Attention Score of 25.7. This one has gotten more attention than average, scoring higher than 70% of its peers.
Older research outputs will score higher simply because they've had more time to accumulate mentions. To account for age we can compare this Altmetric Attention Score to the 310,772 tracked outputs that were published within six weeks on either side of this one in any source. This one has gotten more attention than average, scoring higher than 62% of its contemporaries.
We're also able to compare this research output to 50 others from the same source and published within six weeks on either side of this one. This one has gotten more attention than average, scoring higher than 74% of its contemporaries.